Melanoma prognostic factors found in the dermatopathology report

Clinics in Dermatology

Volumn 27, Issue 1, 2009, Pages 53-74

  Payette, Michael J ^a   Katz III, Marilyn ^a   Grant Kels, Jane M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMELANOTIC MELANOMA; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DESMOPLASTIC MELANOMA; EPIDERMIS HYPERPLASIA; HISTOPATHOLOGY; HUMAN; IN-TRANSIT METASTASIS; LYMPH NODE METASTASIS; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; MITOSIS; NEUROTROPISM; NEVUS; PRIORITY JOURNAL; PROGNOSIS; SATELLITE METASTASIS; SIGNET RING CARCINOMA; SKIN DISEASE; SKIN ULCER; SMALL CELL MELANOMA; SPITZOID MELANOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VERRUCOUS CARCINOMA;

CELL PROLIFERATION; FEMALE; HUMANS; INFLAMMATION; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM REGRESSION, SPONTANEOUS; PROGNOSIS; SKIN NEOPLASMS;

EID: 57649111990     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2008.09.006     Document Type: Article

References (261)

1. Balzi D., Carli P., Giannotti B., et al. Skin melanoma in Italy: a population-based study on survival and prognostic factors. Eur J Cancer 34 (1998) 699-704
2. Lindholm C., Andersson R., Dufmats M., et al. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer 101 (2004) 2067-2078
3. Austin P.F., Cruse C.W., Lyman G., et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1 (1994) 487-494
4. Chao C., Martin II R.C., Ross M.I., et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 11 (2004) 259-264
5. Ferrari A., Bono A., Baldi M., et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 115 (2005) 649-654
6. Sander B., Karlsson P., Rosdahl I., et al. Cutaneous malignant melanoma in Swedish children and teenagers 1973-1992: a clinico-pathological study of 130 cases. Int J Cancer 80 (1999) 646-651
7. Reintgen D.S., Vollmer R., and Seigler H.F. Juvenile malignant melanoma. Surg Gynecol Obstet 168 (1989) 249-253
8. Cochran A.J., Elashoff D., Morton D.L., et al. Individualized prognosis for melanoma patients. Hum Pathol 31 (2000) 327-331
9. Garbe C., Buttner P., Bertz J., et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75 (1995) 2484-2491
10. Karakousis C.P., and Driscoll D.L. Prognostic parameters in localised melanoma: gender versus anatomical location. Eur J Cancer 31A (1995) 320-324
11. Levi F., Randimbison L., La Vecchia C., et al. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer 78 (1998) 315-319
12. Francken A.B., Shaw H.M., Thompson J.F., et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 11 (2004) 426-433
13. Masback A., Olsson H., Westerdahl J., et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 11 (2001) 435-445
14. Ilmonen S., Asko-Seljavaara S., Kariniemi A.L., et al. Prognosis of primary melanoma. Scand J Surg 91 (2002) 166-171
15. Hsueh E.C., Lucci A., Qi K., et al. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer 85 (1999) 383-388
16. Talley L.I., Soong S., Harrison R.A., et al. Clinical outcomes of localized melanoma of the foot: a case-control study. J Clin Epidemiol 51 (1998) 853-857
17. Barnes B.C., Seigler H.F., Saxby T.S., et al. Melanoma of the foot. J Bone Joint Surg Am 76 (1994) 892-898
18. Gillgren P., Mansson-Brahme E., Frisell J., et al. A prospective population-based study of cutaneous malignant melanoma of the head and neck. Laryngoscope 110 (2000) 1498-1504
19. Wanebo H.J., Cooper P.H., Young D.V., et al. Prognostic factors in head and neck melanoma. Effect of lesion location. Cancer 62 (1988) 831-837
20. Lachiewicz A.M., Berwick M., Wiggins C.L., et al. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol 144 (2008) 515-521
21. Leong S.P., Accortt N.A., Essner R., et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg 132 (2006) 370-373
22. Benmeir P., Baruchin A., Lusthaus S., et al. Melanoma of the scalp: the invisible killer. Plast Reconstr Surg 95 (1995) 496-500
23. Shumate C.R., Carlson G.W., Giacco G.G., et al. The prognostic implications of location for scalp melanoma. Am J Surg 162 (1991) 315-319
24. Nagore E., Oliver V., Botella-Estrada R., et al. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 15 (2005) 169-177
25. Law M.M., and Wong J.H. Evaluation of the prognostic significance of the site of origin of cutaneous melanoma. Am Surg 60 (1994) 362-366
26. Hoersch B., Leiter U., and Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol 155 (2006) 771-777
27. Gillgren P., Brattstrom G., Frisell J., et al. Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations. Melanoma Res 15 (2005) 125-132
28. MacKie R.M., Hole D., Hunter J.A., et al. Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. BMJ 315 (1997) 1117-1121
29. Gimotty P.A., Guerry D., Ming M.E., et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 22 (2004) 3668-3676
30. Leiter U., Buettner P.G., Eigentler T.K., et al. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. J Clin Oncol 22 (2004) 3660-3667
31. McKinnon J.G., Yu X.Q., McCarthy W.H., et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 98 (2003) 1223-1231
32. Zalaudek I., Horn M., Richtig E., et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol 148 (2003) 703-708
33. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172 (1970) 902-908
34. Crowson A.N., Magro C.M., and Mihm M.C. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol 19 Suppl 2 (2006) S71-S87
35. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 182 (1975) 572-575
36. Barnhill R.L., Fine J.A., Roush G.C., et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78 (1996) 427-432
37. Rousseau Jr. D.L., Ross M.I., Johnson M.M., et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10 (2003) 569-574
38. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
39. Balch C.M., Murad T.M., Soong S.J., et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188 (1978) 732-742
40. McGovern V.J., Shaw H.M., Milton G.W., et al. Prognostic significance of the histological features of malignant melanoma. Histopathology 3 (1979) 385-393
41. Day Jr. C.L., Sober A.J., Kopf A.W., et al. A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery 89 (1981) 599-603
42. Day Jr. C.L., Sober A.J., Kopf A.W., et al. A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. Am J Surg 142 (1981) 247-251
43. Van Der Esch E.P., Cascinelli N., Preda F., et al. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 48 (1981) 1668-1673
44. Drzewiecki K.T., and Andersen P.K. Survival with malignant melanoma: a regression analysis of prognostic factors. Cancer 49 (1982) 2414-2419
45. Prade M., Bognel C., Charpentier P., et al. Malignant melanoma of the skin: prognostic factors derived from a multifactorial analysis of 239 cases. Am J Dermatopathol 4 (1982) 411-412
46. Day Jr. C.L., Mihm Jr. M.C., Lew R.A., et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg 195 (1982) 35-43
47. Kuehnl-Petzoldt C., Wiebelt H., and Berger H. Prognostic groups of patients with stage I melanoma. Arch Dermatol 119 (1983) 816-819
48. Balch C.M., Soong S.J., Milton G.W., et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 196 (1982) 677-684
49. Urist M.M., Balch C.M., Soong S.J., et al. Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 200 (1984) 769-775
50. Cascinelli N., Marubini E., Morabito A., et al. Prognostic factors for stage I melanoma of the skin: a review. Stat Med 4 (1985) 265-278
51. Shaw H.M., Balch C.M., Soong S.J., et al. Prognostic histopathological factors in malignant melanoma. Pathology 17 (1985) 271-274
52. Sondergaard K., and Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. A multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol 406 (1985) 179-195
53. Meyskens Jr. F.L., Berdeaux D.H., Parks B., et al. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer 62 (1988) 1207-1214
54. Ronan S.G., Han M.C., and Das Gupta T.K. Histologic prognostic indicators in cutaneous malignant melanoma. Semin Oncol 15 (1988) 558-565
55. Clark Jr. W.H., Elder D.E., Guerry IV D., et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81 (1989) 1893-1904
56. Vollmer R.T. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Annu 24 Pt 1 (1989) 383-407
57. Worth A.J., Gallagher R.P., Elwood J.M., et al. Pathologic prognostic factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Int J Cancer 43 (1989) 370-375
58. Heenan P.J., English D.R., Holman C.D., et al. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/1981. Cancer 68 (1991) 2079-2087
59. Haffner A.C., Garbe C., Burg G., et al. The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 66 (1992) 856-861
60. Soong S.J., Shaw H.M., Balch C.M., et al. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 16 (1992) 191-195
61. Straume O., and Akslen L.A. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 78 (1996) 1211-1219
62. Sahin S., Rao B., Kopf A.W., et al. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 80 (1997) 1426-1431
63. Soong S.J., Harrison R.A., McCarthy W.H., et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 67 (1998) 228-233
64. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17 (1999) 976-983
65. Haddad F.F., Stall A., Messina J., et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol 6 (1999) 144-149
66. Balch C.M., Soong S., Ross M.I., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7 (2000) 87-97
67. Wagner J.D., Gordon M.S., Chuang T.Y., et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89 (2000) 453-462
68. Zettersten E., Shaikh L., Ramirez R., et al. Prognostic factors in primary cutaneous melanoma. Surg Clin North Am 83 (2003) 61-75
69. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
70. Karakousis C.P., Emrich L.J., and Rao U. Tumor thickness and prognosis in clinical stage I malignant melanoma. Cancer 64 (1989) 1432-1436
71. Slingluff Jr. C.L., Vollmer R.T., Reintgen D.S., et al. Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg 208 (1988) 150-161
72. Clark Jr. W.H., From L., Bernardino E.A., et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29 (1969) 705-727
73. Morton D.L., Davtyan D.G., Wanek L.A., et al. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 71 (1993) 3737-3743
74. Thorn M., Bergstrom R., Hedblad M., et al. Predictors of late mortality in cutaneous malignant melanoma-a population-based study in Sweden. Int J Cancer 67 (1996) 38-44
75. Marghoob A.A., Koenig K., Bittencourt F.V., et al. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 88 (2000) 589-595
76. Buttner P., Garbe C., Bertz J., et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 75 (1995) 2499-2506
77. Buzaid A.C., Ross M.I., Balch C.M., et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15 (1997) 1039-1051
78. Slingluff Jr. C.L., and Seigler H.F. "Thin" malignant melanoma: risk factors and clinical management. Ann Plast Surg 28 (1992) 89-94
79. Pontikes L.A., Temple W.J., Cassar S.L., et al. Influence of level and depth on recurrence rate in thin melanomas. Am J Surg 165 (1993) 225-228
80. Smolle J., Okcu A., Hofmann-Wellenhof R., et al. Automated measurement of melanoma cross-sectional area. Am J Dermatopathol 20 (1998) 155-159
81. Temple C.F., Huchcroft S.A., Hurlbut D.J., et al. Histologic staging in malignant melanoma: cross-sectional area revisited. J Surg Oncol 69 (1998) 83-87
82. Friedman R.J., Rigel D.S., Kopf A.W., et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator. Preliminary observation. Dermatol Clin 9 (1991) 643-648
83. Gebhart W., and Knobler R. Computer-assisted volumetric analysis of cutaneous malignant melanomas. Am J Dermatopathol 6 Suppl (1984) 93-95
84. Rongioletti F., and Smoller B.R. Unusual histological variants of cutaneous malignant melanoma with some clinical and possible prognostic correlations. J Cutan Pathol 32 (2005) 589-603
85. Larsen T.E., and Grude T.H. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 4. The relation of cross-sectional profile, level of invasion, ulceration and vascular invasion to tumour type and prognosis. Acta Pathol Microbiol Scand [A] 87A (1979) 131-138
86. Siminovitch J.M., Bergfeld W., and Dinner M. Exophytic (pedunculated) malignant melanoma-Cleveland Clinic experience. Ann Plast Surg 5 (1980) 432-435
87. Manci E.A., Balch C.M., Murad T.M., et al. Polypoid melanoma, a virulent variant of the nodular growth pattern. Am J Clin Pathol 75 (1981) 810-815
88. Kuehnl-Petzoldt C., Berger H., and Wiebelt H. Verrucous-keratotic variations of malignant melanoma: a clinicopathological study. Am J Dermatopathol 4 (1982) 403-410
89. Beardmore G.L., Quinn R.L., and Little J.H. Malignant melanoma in Queensland: pathology of 105 fatal cutaneous melanomas. Pathology 2 (1970) 277-286
90. Liestol K., Larsen T.E., and Grude T.H. A Retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 8. The Relative prognostic value of various clinical and histological features evaluated by Cox's regression model. Acta Pathol Microbiol Immunol Scand [A] 90 (1982) 449-454
91. Corona R., Scio M., Mele A., et al. Survival and prognostic factors in patients with localised cutaneous melanoma observed between 1980 and 1991 at the Istituto Dermopatico dell'Immacolata in Rome, Italy. Eur J Cancer 30A (1994) 333-338
92. Heaton K.M., Sussman J.J., Gershenwald J.E., et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 5 (1998) 322-328
93. Berdeaux D.H., Meyskens Jr. F.L., Parks B., et al. Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease. Cancer 63 (1989) 1430-1436
94. Retsas S., Henry K., Mohammed M.Q., et al. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer 38 (2002) 511-516
95. Gordon L.G., Lowry W.S., Pedlow P.J., et al. Poor prognosis for malignant melanoma in Northern Ireland: a multivariate analysis. Br J Cancer 63 (1991) 283-286
96. Lassau N., Koscielny S., Avril M.F., et al. Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of melanomas. AJR Am J Roentgenol 178 (2002) 1547-1551
97. Masback A., Westerdahl J., Ingvar C., et al. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations. Cancer 79 (1997) 275-283
98. Balch C.M., Wilkerson J.A., Murad T.M., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 45 (1980) 3012-3017
99. Kim S.H., Garcia C., Rodriguez J., et al. Prognosis of thick cutaneous melanoma. J Am Coll Surg 188 (1999) 241-247
100. Zettersten E., Sagebiel R.W., Miller III J.R., et al. Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 94 (2002) 1049-1056
101. Otto F.J., Goldmann T., Biess B., et al. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters. Oncology 56 (1999) 208-214
102. Cuellar F.A., Vilalta A., Rull R., et al. Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res 14 (2004) 277-282
103. Glass L.F., Guffey J.M., Schroer K.R., et al. Histopathologic study of recurrent Clark level II melanomas. Semin Surg Oncol 9 (1993) 202-207
104. Chang C.K., Jacobs I.A., Vizgirda V.M., et al. Melanoma in the elderly patient. Arch Surg 138 (2003) 1135-1138
105. Chang C.K., Jacobs I.A., Theodosiou E., et al. Thick melanoma in the elderly. Am Surg 69 (2003) 988-993
106. Grande Sarpa H., Reinke K., Shaikh L., et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol 30 (2006) 1396-1400
107. Schmid-Wendtner M.H., Baumert J., Schmidt M., et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res 11 (2001) 619-626
108. Azzola M.F., Shaw H.M., Thompson J.F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 97 (2003) 1488-1498
109. Barnhill R.L., Katzen J., Spatz A., et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 32 (2005) 268-273
110. Smolle J., Hofmann-Wellenhof R., Kofler R., et al. Tumor cell proliferation and motility estimates are prognostic factors in malignant melanoma. Anal Cell Pathol 5 (1993) 113-124
111. Kashani-Sabet M., Sagebiel R.W., Ferreira C.M., et al. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 20 (2002) 1826-1831
112. Fortes C., Mastroeni S., Sera F., et al. Survival and prognostic variables of cutaneous melanoma observed between 1995 and 2000 at Istituto Dermopatico Dell'Immacolata (IDI-IRCCS), Rome, Italy. Eur J Cancer Prev 15 (2006) 171-177
113. Attis M.G., and Vollmer R.T. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol 127 (2007) 380-384
114. Kashani-Sabet M., Sagebiel R.W., Ferreira C.M., et al. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol 137 (2001) 1169-1173
115. Schmoeckel C., and Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 114 (1978) 871-873
116. Kopf A.W., Gross D.F., Rogers G.S., et al. Prognostic index for malignant melanoma. Cancer 59 (1987) 1236-1241
117. Oliveira Filho R.S., Ferreira L.M., Biasi L.J., et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 36 (2003) 347-350
118. Lefevre M., Vergier B., Balme B., et al. Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol 27 (2003) 717-724
119. Mansson-Brahme E., Carstensen J., Erhardt K., et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer 73 (1994) 2324-2332
120. Paladugu R.R., and Yonemoto R.H. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg 118 (1983) 41-44
121. Sondergaard K., and Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. Virchows Arch A Pathol Anat Histopathol 408 (1985) 241-247
122. Ronan S.G., Eng A.M., Briele H.A., et al. Thin malignant melanomas with regression and metastases. Arch Dermatol 123 (1987) 1326-1330
123. Shaw H.M., Rivers J.K., McCarthy S.W., et al. Cutaneous melanomas exhibiting unusual biologic behavior. World J Surg 16 (1992) 196-202
124. Guitart J., Lowe L., Piepkorn M., et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 138 (2002) 603-608
125. Trau H., Rigel D.S., Harris M.N., et al. Metastases of thin melanomas. Cancer 51 (1983) 553-556
126. Kelly J.W., Sagebiel R.W., and Blois M.S. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer 56 (1985) 2287-2291
127. Briggs J.C., Ibrahim N.B., Hastings A.G., et al. Experience of thin cutaneous melanomas (less than 0.76 mm and less than 0.85 mm thick) in a large plastic surgery unit: a 5 to 17 year follow-up. Br J Plast Surg 37 (1984) 501-506
128. Cooper P.H., Wanebo H.J., and Hagar R.W. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol 121 (1985) 1127-1131
129. Brogelli L., Reali U.M., Moretti S., et al. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res 2 (1992) 87-91
130. McCarthy W.H., Shaw H.M., McCarthy S.W., et al. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol 23 (1996) 709-713
131. Clemente C.G., Mihm Jr. M.C., Bufalino R., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
132. Cecchi R., Buralli L., Innocenti S., et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 34 (2007) 512-515
133. Kaur C., Thomas R.J., Desai N., et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol 61 (2008) 297-300
134. Massi D., Franchi A., Borgognoni L., et al. Thin cutaneous malignant melanomas (
135. Shaw H.M., McCarthy S.W., McCarthy W.H., et al. Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 15 (1989) 257-265
136. Barnhill R.L., and Levy M.A. Regressing thin cutaneous malignant melanomas (
137. Taylor R.C., Patel A., Panageas K.S., et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25 (2007) 869-875
138. Day Jr. C.L., Lew R.A., Mihm Jr. M.C., et al. A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg 195 (1982) 44-49
139. Elder D.E., Guerry IV D., VanHorn M., et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 56 (1985) 413-418
140. Tuthill R.J., Unger J.M., Liu P.Y., et al. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118 (2002) 504-511
141. Hakansson A., Gustafsson B., Krysander L., et al. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer 85 (2001) 1871-1877
142. Ladanyi A., Somlai B., Gilde K., et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10 (2004) 521-530
143. Movassagh M., Spatz A., Davoust J., et al. Selective accumulation of mature DC-Lamp+dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 64 (2004) 2192-2198
144. Ladanyi A., Kiss J., Somlai B., et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56 (2007) 1459-1469
145. Spatz A., Shaw H.M., Crotty K.A., et al. Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (>5 mm). Histopathology 33 (1998) 406-413
146. Anichini A., Vegetti C., and Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53 (2004) 855-864
147. Marincola F.M., Wang E., Herlyn M., et al. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24 (2003) 335-342
148. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
149. Lassau N., Lamuraglia M., Koscielny S., et al. Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer Imaging 6 (2006) 24-29
150. Fallowfield M.E., and Cook M.G. The vascularity of primary cutaneous melanoma. J Pathol 164 (1991) 241-244
151. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66 (1993) 181-196
152. Vlaykova T., Laurila P., Muhonen T., et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 9 (1999) 59-68
153. Carlson J.A., Ross J.S., Slominski A., et al. Molecular diagnostics in melanoma. J Am Acad Dermatol 52 (2005) 743-775 quiz 75-8
154. Barnhill R.L., Fandrey K., Levy M.A., et al. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 67 (1992) 331-337
155. Vlaykova T., Muhonen T., Hahka-Kemppinen M., et al. Vascularity and prognosis of metastatic melanoma. Int J Cancer 74 (1997) 326-329
156. Srivastava A., Laidler P., Davies R.P., et al. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 133 (1988) 419-423
157. Depasquale I., and Thompson W.D. Microvessel density for melanoma prognosis. Histopathology 47 (2005) 186-194
158. Rongioletti F., Miracco C., Gambini C., et al. Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4 mm) cutaneous melanoma. A quantitative assay. Am J Dermatopathol 18 (1996) 474-477
159. Neitzel L.T., Neitzel C.D., Magee K.L., et al. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol 6 (1999) 70-74
160. Erhard H., Rietveld F.J., van Altena M.C., et al. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 7 Suppl 2 (1997) S19-S26
161. Marcoval J., Moreno A., Graells J., et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 24 (1997) 212-218
162. Straume O., Salvesen H.B., and Akslen L.A. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol 15 (1999) 595-599
163. Straume O., and Akslen L.A. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 159 (2001) 223-235
164. Carnochan P., Briggs J.C., Westbury G., et al. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br J Cancer 64 (1991) 102-107
165. Graham C.H., Rivers J., Kerbel R.S., et al. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 145 (1994) 510-514
166. Busam K.J., Berwick M., Blessing K., et al. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol 147 (1995) 1049-1056
167. Ilmonen S., Kariniemi A.L., Vlaykova T., et al. Prognostic value of tumour vascularity in primary melanoma. Melanoma Res 9 (1999) 273-278
168. Balch C.M., Buzaid A.C., Atkins M.B., et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88 (2000) 1484-1491
169. Lugassy C., and Barnhill R.L. Angiotropic melanoma and extravascular migratory metastasis: a review. Adv Anat Pathol 14 (2007) 195-201
170. Barnhill R.L. The biology of melanoma micrometastases. Recent Results Cancer Res 158 (2001) 3-13
171. Lugassy C., Barnhill R.L., and Christensen L. Melanoma and extravascular migratory metastasis. J Cutan Pathol 27 (2000) 481
172. Lugassy C., Dickersin G.R., Christensen L., et al. Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin. J Cutan Pathol 26 (1999) 78-83
173. Lugassy C., Eyden B.P., Christensen L., et al. Angio-tumoral complex in human malignant melanoma characterised by free laminin: ultrastructural and immunohistochemical observations. J Submicrosc Cytol Pathol 29 (1997) 19-28
174. Lugassy C., Shahsafaei A., Bonitz P., et al. Tumor microvessels in melanoma express the beta-2 chain of laminin. Implications for melanoma metastasis. J Cutan Pathol 26 (1999) 222-226
175. Lugassy C., Kleinman H.K., Fernandez P.M., et al. Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis. J Invest Dermatol 119 (2002) 703-704
176. Barnhill R.L., and Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology 36 (2004) 485-490
177. Handley W.S. The pathology of melanotic growths in relation to their operative treatment. Lancet 169 (1907) 996-1003
178. Gerami P., Shea C., and Stone M.S. Angiotropism in epidermotropic metastatic melanoma: another clue to the diagnosis. Am J Dermatopathol 28 (2006) 429-433
179. Johnson C.S., Ramos-Caro F.A., and Hassanein A.M. Ultra-late erysipeloid angiotropic metastatic malignant melanoma. Int J Dermatol 40 (2001) 446-447
180. Shea C.R., Kline M.A., Lugo J., et al. Angiotropic metastatic malignant melanoma. Am J Dermatopathol 17 (1995) 58-62
181. Moreno A., Espanol I., and Romagosa V. Angiotropic malignant melanoma. Report of two cases. J Cutan Pathol 19 (1992) 325-329
182. Barnhill R., Dy K., and Lugassy C. Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis. J Invest Dermatol 119 (2002) 705-706
183. Lugassy C., Vernon S.E., Busam K., et al. Angiotropism of human melanoma: studies involving in transit and other cutaneous metastases and the chicken chorioallantoic membrane: implications for extravascular melanoma invasion and metastasis. Am J Dermatopathol 28 (2006) 187-193
184. Setala L.P., Kosma V.M., Marin S., et al. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 74 (1996) 766-772
185. Pinder S.E., Ellis I.O., Galea M., et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24 (1994) 41-47
186. Sondergaard K., and Schou G. Therapeutic and clinico-pathological factors in the survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I. A multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol 408 (1985) 249-258
187. Bachaud J.M., Shubinski R., Boussin G., et al. Stage I cutaneous malignant melanoma: risk factors of loco-regional recurrence after wide local excision and clinical perspectives. Eur J Surg Oncol 18 (1992) 442-448
188. Gamel J.W., George S.L., Stanley W.E., et al. Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex. Cancer 72 (1993) 1219-1223
189. MacKie R.M., Aitchison T., Sirel J.M., et al. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer 71 (1995) 173-176
190. Thorn M., Ponten F., Bergstrom R., et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 86 (1994) 761-769
191. Lugassy C., Eyden B.P., Christensen L., et al. Is the angio-tumoral complex in human malignant melanoma a marker of non-hematogenous migration? [abstract]. Melanoma Res 7 (1997) S95
192. Barnhill R.L., Sagebiel R.W., and Lugassy C. Angiotropic melanoma: report of seven additional cases. [abstract]. J Cutan Pathol 27 (2000) 548
193. Schmoeckel C., Bockelbrink A., Bockelbrink H., et al. Low-and high-risk malignant melanoma-I. Evaluation of clinical and histological prognosticators in 585 cases. Eur J Cancer Clin Oncol 19 (1983) 227-235
194. Arrington III J.H., Reed R.J., Ichinose H., et al. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol 1 (1977) 131-143
195. MacKie R.M. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 25 (2000) 471-475
196. Swetter SM. Dermatological perspectives of malignant melanoma. Surg Clin North Am 2003;83:77-95, vi.
197. Weyers W., Euler M., Diaz-Cascajo C., et al. Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer 86 (1999) 288-299
198. Hacene K., Le Doussal V., Brunet M., et al. Prognostic index for clinical Stage I cutaneous malignant melanoma. Cancer Res 43 (1983) 2991-2996
199. Ringborg U., Afzelius L.E., Lagerlof B., et al. Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish Melanoma Study Group. Cancer 71 (1993) 751-758
200. Crocetti E., Mangone L., Lo Scocco G., et al. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study. Melanoma Res 16 (2006) 429-433
201. Golger A., Young D.S., Ghazarian D., et al. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg 133 (2007) 442-447
202. Kuno Y., Ishihara K., Yamazaki N., et al. Clinical and pathological features of cutaneous malignant melanoma: a retrospective analysis of 124 Japanese patients. Jpn J Clin Oncol 26 (1996) 144-151
203. Giuliano A.E., Cochran A.J., and Morton D.L. Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol 9 (1982) 442-447
204. McGovern V.J., Shaw H.M., Milton G.W., et al. Cell type and pigment content as prognostic indicators in cutaneous malignant melanoma. In: Ackerman A.B. (Ed). Pathology of malignant melanoma (1981), Masson, New York 327-332
205. Schuchter L., Schultz D.J., Synnestvedt M., et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 125 (1996) 369-375
206. Koch S.E., and Lange J.R. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol 42 (2000) 731-734
207. Leon P., Daly J.M., Synnestvedt M., et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 126 (1991) 1461-1468
208. Pol-Rodriquez M., Lee S., Silvers D.N., et al. Influence of age on survival in childhood spitzoid melanomas. Cancer 109 (2007) 1579-1583
209. Fabrizi G., and Massi G. Spitzoid malignant melanoma in teenagers: an entity with no better prognosis than that of other forms of melanoma. Histopathology 38 (2001) 448-453
210. Magro C.M., Crowson A.N., and Mihm M.C. Unusual variants of malignant melanoma. Mod Pathol 19 Suppl 2 (2006) S41-S70
211. Won J.H., Ahn S.K., Lee S.H., et al. Signet-ring cell melanoma: poor prognostic factor?. Br J Dermatol 131 (1994) 135-137
212. Breier F., Feldmann R., Fellenz C., et al. Primary invasive signet-ring cell melanoma. J Cutan Pathol 26 (1999) 533-536
213. Rutten A., Huschka U., Requena C., et al. Primary cutaneous signet-ring cell melanoma: a clinico-pathologic and immunohistochemical study of two cases. Am J Dermatopathol 25 (2003) 418-422
214. Podnos Y.D., Jimenez J.C., Zainabadi K., et al. Minimal deviation melanoma. Cancer Treat Rev 28 (2002) 219-221
215. Phillips M.E., Margolis R.J., Merot Y., et al. The spectrum of minimal deviation melanoma: a clinicopathologic study of 21 cases. Hum Pathol 17 (1986) 796-806
216. Schmoeckel C., Castro C.E., and Braun-Falco O. Nevoid malignant melanoma. Arch Dermatol Res 277 (1985) 362-369
217. Zembowicz A., McCusker M., Chiarelli C., et al. Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature. Am J Dermatopathol 23 (2001) 167-175
218. Busam K.J., Mujumdar U., Hummer A.J., et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol 28 (2004) 1518-1525
219. Busam K.J. Cutaneous desmoplastic melanoma. Adv Anat Pathol 12 (2005) 92-102
220. Gyorki D.E., Busam K., Panageas K., et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 10 (2003) 403-407
221. Payne W.G., Kearney R., Wells K., et al. Desmoplastic melanoma. Am Surg 67 (2001) 1004-1006
222. Jaroszewski D.E., Pockaj B.A., DiCaudo D.J., et al. The clinical behavior of desmoplastic melanoma. Am J Surg 182 (2001) 590-595
223. Quinn M.J., Crotty K.A., Thompson J.F., et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 83 (1998) 1128-1135
224. Carlson J.A., Dickersin G.R., Sober A.J., et al. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer 75 (1995) 478-494
225. Skelton H.G., Smith K.J., Laskin W.B., et al. Desmoplastic malignant melanoma. J Am Acad Dermatol 32 (1995) 717-725
226. Conley J., Lattes R., and Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 28 (1971) 914-936
227. Egbert B., Kempson R., and Sagebiel R. Desmoplastic malignant melanoma. A clinicohistopathologic study of 25 cases. Cancer 62 (1988) 2033-2041
228. Baer S.C., Schultz D., Synnestvedt M., et al. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer 76 (1995) 2242-2247
229. Day Jr. C.L., Sober A.J., Lew R.A., et al. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 47 (1981) 955-962
230. Balch C.M., Soong S.J., Murad T.M., et al. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 86 (1979) 343-351
231. Hawkins W.G., Busam K.J., Ben-Porat L., et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 12 (2005) 207-213
232. Su L.D., Fullen D.R., Lowe L., et al. Desmoplastic and neurotropic melanoma. Cancer 100 (2004) 598-604
233. Thelmo M.C., Sagebiel R.W., Treseler P.A., et al. Evaluation of sentinel lymph node status in spindle cell melanomas. J Am Acad Dermatol 44 (2001) 451-455
234. Cummins D.L., Esche C., Barrett T.L., et al. Lymph node biopsy results for desmoplastic malignant melanoma. Cutis 79 (2007) 390-394
235. Reed R.J. Minimal deviation melanoma. In: Mihm M.C., Murphy G.F., and Kaufman N. (Eds). Pathobiology and recognition of malignant melanoma (1988), Williams and Wilkins, Baltimore 110-152
236. Livestro D.P., Muzikansky A., Kaine E.M., et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol 23 (2005) 6739-6746
237. Shaw H.M., Quinn M.J., Scolyer R.A., et al. Survival in patients with desmoplastic melanoma. J Clin Oncol 24 (2006) e12 author reply, e3
238. Reed R.J., and Leonard D.D. Neurotropic melanoma. A variant of desmoplastic melanoma. Am J Surg Pathol 3 (1979) 301-311
239. Newlin H.E., Morris C.G., Amdur R.J., et al. Neurotropic melanoma of the head and neck with clinical perineural invasion. Am J Clin Oncol 28 (2005) 399-402
240. Anderson T.D., Weber R.S., Guerry D., et al. Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy. Head Neck 24 (2002) 1068-1071
241. Madrigal B., Fresno M.F., Junquera L., et al. De novo desmoplastic neurotropic melanoma of the lower lip: a neoplasm with ominous behavior. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86 (1998) 452-456
242. Lin D., Kashani-Sabet M., McCalmont T., et al. Neurotropic melanoma invading the inferior alveolar nerve. J Am Acad Dermatol 53 (2005) S120-S122
243. Fabre B., Gigaud M., Lamant L., et al. [Trigeminal neuralgia presenting as a deep recurrent desmoplastic neurotropic melanoma of a lentigo maligna]. French. Ann Dermatol Venereol 130 (2003) 1044-1046
244. Byrne P.R., Maiman M., Mikhail A., et al. Neurotropic desmoplastic melanoma: a rare vulvar malignancy. Gynecol Oncol 56 (1995) 289-293
245. Barnhill R.L., and Bolognia J.L. Neurotropic melanoma with prominent melanization. J Cutan Pathol 22 (1995) 450-459
246. Larsen T.E., and Grude T.H. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 2. The relation of cell type, pigmentation, atypia and mitotic count to histological type and prognosis. Acta Pathol Microbiol Scand [A] 86A (1978) 513-522
247. Weatherhead S.C., Haniffa M., and Lawrence C.M. Melanomas arising from naevi and de novo melanomas-does origin matter?. Br J Dermatol 156 (2007) 72-76
248. Friedman R.J., Rigel D.S., Kopf A.W., et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol 119 (1983) 455-462
249. Drunkenmolle E., Marsch W., Lubbe D., et al. Paratumoral epidermal hyperplasia: a novel prognostic factor in thick primary melanoma of the skin?. Am J Dermatopathol 27 (2005) 482-488
250. Kaddu S., Smolle J., Zenahlik P., et al. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res 12 (2002) 271-278
251. Mott R.T., Rosenberg A., Livingston S., et al. Melanoma associated with pseudoepitheliomatous hyperplasia: a case series and investigation into the role of epidermal growth factor receptor. J Cutan Pathol 29 (2002) 490-497
252. Hanly A.J., Jorda M., and Elgart G.W. Cutaneous malignant melanoma associated with extensive pseudoepitheliomatous hyperplasia. Report of a case and discussion of the origin of pseudoepitheliomatous hyperplasia. J Cutan Pathol 27 (2000) 153-156
253. Reis-Filho J.S., Gasparetto E.L., Schmitt F.C., et al. Pseudoepitheliomatous hyperplasia in cutaneous malignant melanoma: a rare and misleading feature. J Cutan Pathol 28 (2001) 496-497
254. Nakayama T., Taback B., Turner R., et al. Molecular clonality of in-transit melanoma metastasis. Am J Pathol 158 (2001) 1371-1378
255. Wong J.H., Cagle L.A., Kopald K.H., et al. Natural history and selective management of in transit melanoma. J Surg Oncol 44 (1990) 146-150
256. Shaikh L., Sagebiel R.W., Ferreira C.M., et al. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol 141 (2005) 739-742
257. Day Jr. C.L., Harrist T.J., Gorstein F., et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 194 (1981) 108-112
258. Harrist T.J., Rigel D.S., Day Jr. C.L., et al. "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 53 (1984) 2183-2187
259. Singletary S.E., Tucker S.L., and Boddie Jr. A.W. Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer 61 (1988) 1437-1440
260. Cascinelli N., Bufalino R., Marolda R., et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 12 (1986) 175-180
261. Sutherland C.M., Mather F.J., and Krementz E.T. Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet 164 (1987) 111-118